Innate Pharma S.A. (LON:0EVI)

Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of GBP 130.12 million. The enterprise value is 101.19 million.

Market Cap	130.12M
Enterprise Value	101.19M

Important Dates

The next estimated earnings date is Thursday, March 26, 2026.

Earnings Date	Mar 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	92.17M
Shares Outstanding	n/a
Shares Change (YoY)	+4.15%
Shares Change (QoQ)	+7.02%
Owned by Insiders (%)	0.98%
Owned by Institutions (%)	1.88%
Float	60.15M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	12.01
PB Ratio	29.51
P/TBV Ratio	29.51
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-2.56
EV / Sales	9.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.86

Financial Position

The company has a current ratio of 2.21, with a Debt / Equity ratio of 5.25.

Current Ratio	2.21
Quick Ratio	2.08
Debt / Equity	5.25
Debt / EBITDA	n/a
Debt / FCF	-0.66
Interest Coverage	-102.40

Financial Efficiency

Return on equity (ROE) is -271.37% and return on invested capital (ROIC) is -65.68%.

Return on Equity (ROE)	-271.37%
Return on Assets (ROA)	-25.92%
Return on Invested Capital (ROIC)	-65.68%
Return on Capital Employed (ROCE)	-79.81%
Revenue Per Employee	62,250
Profits Per Employee	-226,866
Employee Count	181
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +9.80% in the last 52 weeks. The beta is 0.51, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.51
52-Week Price Change	+9.80%
50-Day Moving Average	1.69
200-Day Moving Average	1.77
Relative Strength Index (RSI)	42.92
Average Volume (20 Days)	5,264

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of GBP 10.83 million and -39.47 million in losses. Loss per share was -0.47.

Revenue	10.83M
Gross Profit	-26.39M
Operating Income	-43.45M
Pretax Income	-39.47M
Net Income	-39.47M
EBITDA	-42.66M
EBIT	-43.45M
Loss Per Share	-0.47

Balance Sheet

The company has 51.45 million in cash and 23.17 million in debt, giving a net cash position of 28.29 million.

Cash & Cash Equivalents	51.45M
Total Debt	23.17M
Net Cash	28.29M
Net Cash Per Share	n/a
Equity (Book Value)	4.41M
Book Value Per Share	0.05
Working Capital	30.47M

Cash Flow

In the last 12 months, operating cash flow was -35.23 million and capital expenditures -142,294, giving a free cash flow of -35.37 million.

Operating Cash Flow	-35.23M
Capital Expenditures	-142,294
Free Cash Flow	-35.37M
FCF Per Share	n/a

Margins

Gross Margin	-243.65%
Operating Margin	-401.15%
Pretax Margin	-364.44%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.15%
Shareholder Yield	-4.15%
Earnings Yield	-30.34%
FCF Yield	-27.18%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -6.27 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.27
Piotroski F-Score	2